Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Teva Parenteral Medicines, Inc.
EIR
•Teva Parenteral Medicines, Inc.•April 24, 2012

Teva Parenteral Medicines, Inc. – FDA EIR, Apr 24, 2012

Record Details

An FDA inspection was conducted at Teva Parenteral Medicines Inc. in Irvine, CA, from April 3 to April 24, 2012. This comprehensive Good Manufacturing Practice (GMP) and compliance follow-up inspection, under Compliance Program 7356.002, focused on their parenteral drug manufacturing operations. The inspection identified significant issues, leading to the issuance of a 2-item FDA-483 (Inspectional Observations).

A primary concern was product quality and control, evidenced by multiple Class II and III recalls of sterile injectable products. These recalls involved various products, including Bumetanide Injection, Tobramycin Sulfate Injection, Oxytocin Injection, Medroxyprogesterone Acetate Injectable Suspension, Ifosfamide Injection, and Pancuronium Bromide Injection. The reasons for recall included particulate matter, lack of sterility assurance, impurities, degradation products, and out-of-specification pH.

A critical violation involved the manufacture of Daunorubicin HCl Injection without a fully validated testing method, despite being a drug shortage item. Additionally, previous inspections revealed inadequate stability-indicating methods for other products, contributing to subsequent recalls. The firm's process for Field Alert Reports (FARs) was also reviewed, noting potential issues with reporting timeframes.

Teva Parenteral Medicines Inc. was required to address these deficiencies, demonstrating effective remediation and robust quality systems to ensure the safety, identity, strength, quality, and purity of its drug products.

Company
Teva Parenteral Medicines, Inc.
Inspection date
April 24, 2012
Product type
Drugs
Office
Los Angeles District Office
People
  • Caryn Mcnab
  • Jennifer M. Gogley (Laboratory Director)
  • Manjula Ghosh (company_representative)
  • Bichsa T. Tran (investigator)
  • Adam Fox (company_representative)
View Company Profile

ID · b299d610-ae8c-472a-874f-b86459f675d6

Other documents for Teva Parenteral Medicines, Inc.
  • 483 - 2021-08-20August 20, 2021
  • 483 - 2019-08-30August 30, 2019
  • EIR - 2019-08-30August 30, 2019
  • 483 - 2019-01-18January 18, 2019
  • 483 - 2016-07-29July 29, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Teva Parenteral Medicines, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.